Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled (2: 1), Multicenter Clinical Study (IIB) for the Treatment of Stage Ⅳ Soft Tissue Sarcoma With Recombinant Human Endostatin(Endostar) Combined With Chemotherapy

Next Previous
X
Search
Trial Profile

Randomized, Double-blind, Placebo-controlled (2: 1), Multicenter Clinical Study (IIB) for the Treatment of Stage Ⅳ Soft Tissue Sarcoma With Recombinant Human Endostatin(Endostar) Combined With Chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary) ; Docetaxel; Gemcitabine; Ifosfamide; Pirarubicin
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Dec 2019 Status changed from recruiting to completed.
    • 04 Jun 2019 Results assessing chemotherapy combined with antiangiogenesis drugs in stage IV sarcoma patients using data from NCT03121833 and NCT03121846 studies, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 15 May 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top